Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;1.061;73;1.133;
%Companies according to biotechnology used: Genetic code;30;50;32;
%Companies according to biotechnology used: Functional units;40;51;41;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;26;46;27;
%Companies according to biotechnology used: Bioprocesses;47;64;48;
%Companies according to biotechnology used: Sub-cellular organisms;8;20;8;
%Companies according to biotechnology used: Bio-computing;21;31;21;
%Companies according to biotechnology used: Nanobiotechnology;14;18;14;
%Companies according to biotechnology used: Other;13;10;13;
Companies in which biotechnology activities are: Main and/or exclusive;549;15;564;
Companies in which biotechnology activities are: A secondary line of business;193;19;212;
Companies in which biotechnology activities are: A tool necessary for production;319;38;358;
%Company by field(s) of ultimate application of biotechnology use: Human Health;50;51;50;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;20;1;19;
%Company by field(s) of ultimate application of biotechnology use: Food products;29;36;29;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;18;21;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;11;13;
%Company by field(s) of ultimate application of biotechnology use: Industry;14;7;13;
Personnel in R&D in biotechnology (no. of persons);7.883;2.823;10.706;
Personnel in R&D in biotechnology (no. of persons): Researchers;4.706;1.521;6.227;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3.177;1.302;4.479;
Personnel in R&D in biotechnology (no. of persons): women;4.068;1.727;5.795;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.417;852;3.269;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1.652;875;2.527;
Personnel in R&D in biotechnology (FTE);5.599;2.117,4;7.716,4;
Personnel in R&D in biotechnology (FTE): Researchers;3.511,8;1.091,3;4.603,1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.087,2;1.026,1;3.113,3;
Personnel in R&D in biotechnology (FTE): women;2.969,5;1.323,4;4.292,9;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1.832,2;614,2;2.446,4;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.137,3;709,2;1.846,5;
Internal expenditure on R&D (thousands of euros);452.121;163.932;616.053;
1) By nature of the expense: Current expenses;413.906;160.340;574.245;
1.1) Remuneration to researchers;160.779;60.962;221.741;
1.2) Remuneration to technicians and assistants;61.960;40.504;102.464;
1.3) Other current expenses;191.167;58.874;250.041;
2) By nature of the expense: Capital expenses;38.215;3.593;41.808;
2.1) Land and buildings;4.988;371;5.359;
2.2) Equipment and instruments;26.997;2.493;29.489;
2.3) Acquisition of specific R&D software;1.716;590;2.306;
2.4) Otros productos de propiedad intelectual específicos para I+D;4.515;139;4.654;
1) By origin of the funds: National funds;388.127;123.833;511.960;
1.1) Own funds;294.928;87.407;382.335;
1.2) From companies;29.072;15.952;45.024;
1.3) Public Administration funds;60.976;11.410;72.387;
1.4) From Universities;363;0;363;
1.5) From non profit private institutions;2.788;9.064;11.851;
1) By origin of the funds: Foreign funds;63.994;40.100;104.093;
2.1) From EU programmes;18.363;3.462;21.825;
2.2) Other foreign funds;45.631;36.638;82.269;
Purchase of R&D services in biotechnology (thousands of euros);88.908;55.434;144.342;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;35.758;34.700;70.458;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;53.150;20.734;73.885;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;49;29;48;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;13;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;15;13;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;12;14;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;16;14;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17;10;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16;14;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;36;35;36;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;49;39;49;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;18;14;18;
% Companies that have requested biotechnology patents in Biotechnology;16;12;16;
Number of patents requested;570;63;633;
% Companies with income of an international origin related to biotechnological activities;24,2;20,7;24;
% Turnover representing income of an international origin related to biotechnological activities;6,1;0,9;1,4;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;37,3;75,7;57,3;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;62,7;24,3;42,7;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;96,3;69,4;82,3;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;2,4;29,4;16,5;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,1;0,9;1;
% Income of an international origin related with activities according to the classification: Other;0,2;0,3;0,3;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute